Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs

Scooter Willis, Pradip De, Nandini Dey, Bradley Long, Brandon Young, Joseph A. Sparano, Victoria Wang, Nancy E. Davidson, Brian R. Leyland-Jones

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Triple negative (TN) breast cancers which lack expression of the estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors convey a poor prognosis due in part to a lack of targeted therapies. Methods: To identify viable targets for the treatment of TN disease, we have conducted a gene set enrichment analysis (GSEA) on seven different breast cancer whole genome gene expression cohorts comparing TN vs. ER. + HER2. - to identify consistently enriched genes that share a common promoter motif. The seven cohorts were profiled on three different genome expression platforms (Affymetrix, Illumina and RNAseq) consisting in total of 2088 samples with IHC metadata. Results: GSEA identified enriched gene expression patterns in TN samples that share common promoter motifs associated with SOX9, E2F1, HIF1A, HMGA1, MYC BACH2, CEBPB, and GCNF/NR6A1. Unexpectedly, NR6A1 an orphan nuclear receptor normally expressed in germ cells of gonads is highly expressed in TN and ER. + HER2. - samples making it an ideal drug target. Conclusion: With the increasing number of large sample size breast cancer cohorts, an exploratory analysis of genes that are consistently enriched in TN sharing common promoter motifs allows for the identification of possible therapeutic targets with extensive validation in patient derived data sets.

Original languageEnglish (US)
Pages (from-to)129-141
Number of pages13
JournalMeta Gene
Volume4
DOIs
StatePublished - Jun 1 2015

Fingerprint

Triple Negative Breast Neoplasms
Transcription Factors
Estrogens
Epidermal Growth Factor
Pharmaceutical Preparations
Genes
Genome
Orphan Nuclear Receptors
Breast Neoplasms
Gene Expression
Gonads
Therapeutics
Germ Cells
Sample Size
Progesterone
Cohort Studies

Keywords

  • Breast cancer
  • ER+
  • GSEA
  • NR6A1
  • Triple negative

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. / Willis, Scooter; De, Pradip; Dey, Nandini; Long, Bradley; Young, Brandon; Sparano, Joseph A.; Wang, Victoria; Davidson, Nancy E.; Leyland-Jones, Brian R.

In: Meta Gene, Vol. 4, 01.06.2015, p. 129-141.

Research output: Contribution to journalArticle

Willis, Scooter ; De, Pradip ; Dey, Nandini ; Long, Bradley ; Young, Brandon ; Sparano, Joseph A. ; Wang, Victoria ; Davidson, Nancy E. ; Leyland-Jones, Brian R. / Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. In: Meta Gene. 2015 ; Vol. 4. pp. 129-141.
@article{c137518b727e42af8f04f4c64c0624f4,
title = "Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs",
abstract = "Purpose: Triple negative (TN) breast cancers which lack expression of the estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors convey a poor prognosis due in part to a lack of targeted therapies. Methods: To identify viable targets for the treatment of TN disease, we have conducted a gene set enrichment analysis (GSEA) on seven different breast cancer whole genome gene expression cohorts comparing TN vs. ER. + HER2. - to identify consistently enriched genes that share a common promoter motif. The seven cohorts were profiled on three different genome expression platforms (Affymetrix, Illumina and RNAseq) consisting in total of 2088 samples with IHC metadata. Results: GSEA identified enriched gene expression patterns in TN samples that share common promoter motifs associated with SOX9, E2F1, HIF1A, HMGA1, MYC BACH2, CEBPB, and GCNF/NR6A1. Unexpectedly, NR6A1 an orphan nuclear receptor normally expressed in germ cells of gonads is highly expressed in TN and ER. + HER2. - samples making it an ideal drug target. Conclusion: With the increasing number of large sample size breast cancer cohorts, an exploratory analysis of genes that are consistently enriched in TN sharing common promoter motifs allows for the identification of possible therapeutic targets with extensive validation in patient derived data sets.",
keywords = "Breast cancer, ER+, GSEA, NR6A1, Triple negative",
author = "Scooter Willis and Pradip De and Nandini Dey and Bradley Long and Brandon Young and Sparano, {Joseph A.} and Victoria Wang and Davidson, {Nancy E.} and Leyland-Jones, {Brian R.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.mgene.2015.04.002",
language = "English (US)",
volume = "4",
pages = "129--141",
journal = "Meta Gene",
issn = "2214-5400",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs

AU - Willis, Scooter

AU - De, Pradip

AU - Dey, Nandini

AU - Long, Bradley

AU - Young, Brandon

AU - Sparano, Joseph A.

AU - Wang, Victoria

AU - Davidson, Nancy E.

AU - Leyland-Jones, Brian R.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Purpose: Triple negative (TN) breast cancers which lack expression of the estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors convey a poor prognosis due in part to a lack of targeted therapies. Methods: To identify viable targets for the treatment of TN disease, we have conducted a gene set enrichment analysis (GSEA) on seven different breast cancer whole genome gene expression cohorts comparing TN vs. ER. + HER2. - to identify consistently enriched genes that share a common promoter motif. The seven cohorts were profiled on three different genome expression platforms (Affymetrix, Illumina and RNAseq) consisting in total of 2088 samples with IHC metadata. Results: GSEA identified enriched gene expression patterns in TN samples that share common promoter motifs associated with SOX9, E2F1, HIF1A, HMGA1, MYC BACH2, CEBPB, and GCNF/NR6A1. Unexpectedly, NR6A1 an orphan nuclear receptor normally expressed in germ cells of gonads is highly expressed in TN and ER. + HER2. - samples making it an ideal drug target. Conclusion: With the increasing number of large sample size breast cancer cohorts, an exploratory analysis of genes that are consistently enriched in TN sharing common promoter motifs allows for the identification of possible therapeutic targets with extensive validation in patient derived data sets.

AB - Purpose: Triple negative (TN) breast cancers which lack expression of the estrogen (ER), progesterone (PR), and human epidermal growth factor 2 (HER2) receptors convey a poor prognosis due in part to a lack of targeted therapies. Methods: To identify viable targets for the treatment of TN disease, we have conducted a gene set enrichment analysis (GSEA) on seven different breast cancer whole genome gene expression cohorts comparing TN vs. ER. + HER2. - to identify consistently enriched genes that share a common promoter motif. The seven cohorts were profiled on three different genome expression platforms (Affymetrix, Illumina and RNAseq) consisting in total of 2088 samples with IHC metadata. Results: GSEA identified enriched gene expression patterns in TN samples that share common promoter motifs associated with SOX9, E2F1, HIF1A, HMGA1, MYC BACH2, CEBPB, and GCNF/NR6A1. Unexpectedly, NR6A1 an orphan nuclear receptor normally expressed in germ cells of gonads is highly expressed in TN and ER. + HER2. - samples making it an ideal drug target. Conclusion: With the increasing number of large sample size breast cancer cohorts, an exploratory analysis of genes that are consistently enriched in TN sharing common promoter motifs allows for the identification of possible therapeutic targets with extensive validation in patient derived data sets.

KW - Breast cancer

KW - ER+

KW - GSEA

KW - NR6A1

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=84929299585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929299585&partnerID=8YFLogxK

U2 - 10.1016/j.mgene.2015.04.002

DO - 10.1016/j.mgene.2015.04.002

M3 - Article

AN - SCOPUS:84929299585

VL - 4

SP - 129

EP - 141

JO - Meta Gene

JF - Meta Gene

SN - 2214-5400

ER -